Carbapenem-resistant Pseudomonas Aeruginosa: the SAMPAN Study.
Study Details
Study Description
Brief Summary
Pseudomonas aeruginosa causes severe infections in hospitalized patients. The worldwide emergence of carbapenem-resistant P. aeruginosa (CR-PA) makes infections by these pathogens almost untreatable. The World Health Organization now ranks CR-PA highest in the list of 'urgent threats'. Information for action to prevent further emergence has to come from insight into sources and transmission routes through smart surveillance. At present, a smart surveillance strategy is not available for CR-PA. The aim of this project is to develop a globally-applicable smart surveillance strategy to guide action against the spread of CR-PA. Since P. aeruginosa prefers moist niches, we will focus on the human-water interface. First, highly-sensitive methods to detect CR-PA in specific environmental and human niches will be developed. Subsequently, CR-PA will be collected in three study sites with increasing prevalences of CR-PA, increasingly warmer climates, and different water situations: Rotterdam (The Netherlands), Rome (Italy), Jakarta (Indonesia). CR-PA will be searched for in a variety of niches in the environment outside and inside the hospital, and in healthy humans and hospitalized patients. Whole genome sequencing will be performed to compare the CR-PA from different sources and identify transmission routes. Our project will provide insight into the relative contribution of the different potential reservoirs of CR-PA to its spread in different settings which will be used for the development of a globally-applicable surveillance strategy for CR-PA to guide preventive actions.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Patients at the moment of their admission to the hospital in one of the three cities Swabs will be taken from patients who are willing to participate. |
|
| Healthy volunteers living in "high-risk areas" in one of the three cities. Swabs will be taken from healthy volunteers who are willing to participate. |
Outcome Measures
Primary Outcome Measures
- Prevalences of CR-PA in samples taken from healthy persons and patients at the moment of their admission to the hospital in the three cities. [2023/2024]
Secondary Outcome Measures
- Risk factors for carriage of CR-PA in healthy persons and patients. [2023/2024]
Eligibility Criteria
Criteria
Inclusion Criteria healthy individuals:
- All healthy individuals living in a "high-risk area" in Rotterdam, Rome or Jakarta.
Exclusion Criteria healthy individuals:
- No signed consent sheet
Inclusion Criteria patients:
-
Must be aged 18 years or older;
-
Should be capable of providing answers to the questions in the questionnaire by himself/herself;
-
Should have a minimum expected length of stay of at least 24 hours;
-
Inclusion only once during the sampling year.
Exclusion Criteria patients:
-
Cystic fibrosis patients
-
No signed consent sheet.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Dr Cipto Mangunkusumo General Hospital | Jakarta | Indonesia | ||
| 2 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Roma | Italy | ||
| 3 | Erasmus Medical Center | Rotterdam | Zuid-Holland | Netherlands | 3015 GD |
Sponsors and Collaborators
- Erasmus Medical Center
- Dr Cipto Mangunkusumo General Hospital
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 5025